Immunosenescence: implications for vaccination programs in the elderly

References

• Rehman T. Role of the gut microbiota in age-related chronic inflammation. Endocr Metab Immune Disord Drug Targets. 2012;12:361–367.
   PubMedGoogle Scholar
• Heron M, Tejada-Vera B. Deaths: leading causes for 2005. Natl Vital Stat Rep. 2009;58(8):1–97.
   Google Scholar
• Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med. 2005;165(3):265–272.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Estimates of deaths associated with seasonal influenza – United States, 1976–2007. MMWR Morb Mortal Wkly Rep. 2010;59(33):1057–1062
   PubMedGoogle Scholar
• National Center for Health Statistics. National Vital Statistics Report. Deaths: Final Data for 2006. Hyattsville, MD: National Center for Health Statistics; 2009.
   Google Scholar
• Johnstone J, Eurich DT, Majumdar S, Jin Y, Marrie T. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore). 2008;87(6):329–334.
   PubMed Web of Science ®Google Scholar
• Shah FA, Pike F, Alvarez K, et al. Bidirectional relationship between cognitive function and pneumonia. Am J Respir Crit Care Med. 2013;188(5):586–592.
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264–274.
   PubMed Web of Science ®Google Scholar
• Saliba W, Fediai A, Edelstein H, Markel A, Raz R. Trends in the burden of infectious disease hospitalizations among the elderly in the last decade. Eur J Intern Med. 2013;24(6):536–540.
   Web of Science ®Google Scholar
• Public Health Agency of Canada [homepage on the Internet]. Canadian Immunization Guide. National Advisory Committee on Immunization; 2013 [updated June 22, 2015]. Available from: http://www.phac-aspc.gc.ca/publicat/cig-gci/p01-14-eng.php. Accessed August 27, 2013.
   Google Scholar
• Goronzy JJ, Weyand CM. Understanding immunosenescence to improve responses to vaccines. Nat Immunol. 2013;4(5):428–436.
   Google Scholar
• Lang P, Mendes A, Socquet J, Assir N, Govind S, Aspinall R. Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence. Clin Interv Aging. 2012;7:55–64.
   PubMed Web of Science ®Google Scholar
• Williams WW, Lu PJ, O’Halloran A, et al; Centers for Disease Control and Prevention. Noninfluenza vaccination coverage among adults – United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(5):95–102.
   PubMed Web of Science ®Google Scholar
• Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly [review]. Cochrane Database Syst Rev. 2010;2:CD004876.
   Google Scholar
• Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet. 2005;366:1165–1174.
   PubMed Web of Science ®Google Scholar
• Metersky M, Masterton R, Lode H, File T, Babinchak T. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16(5):e321–e331.
   PubMed Web of Science ®Google Scholar
• Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults [review]. Cochrane Database Syst Rev. 2008;1:CD000422.
   Google Scholar
• Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥60 years: 3 years of follow-up in the CAPAMIS study. Clin Infect Dis. 2014;58(7):909–917.
   PubMed Web of Science ®Google Scholar
• Rudnick W, Liu Z, Shigayeva A, et al; Toronto Invasive Bacterial Diseases Network. Pneumococcal vaccination programs and the burden of invasive pneumococcal disease in Ontario, Canada, 1995–2011. Vaccine. 2013;31(49):5863–5871.
   PubMed Web of Science ®Google Scholar
• Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hosen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged 65+: a retrospective case-control study. Clin Infect Dis. 2015;60(10):1472–1480.
   PubMed Web of Science ®Google Scholar
• Huss A, Scott P, Stuck AE, Trotter C, Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ. 2009;180(1):48–58.
   PubMed Web of Science ®Google Scholar
• Franceschi C, Capri M, Monti D, et al. Inflammaging and anti- inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev. 2007;128(1):92–105.
   PubMed Web of Science ®Google Scholar
• Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol. 2004;5:971–974.
   PubMed Web of Science ®Google Scholar
• Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol. 2002;270:81–92.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Medzhitov R. Toll-like receptor?control of the adaptive immune responses. Nat Immunol. 2004;5:987–995.
   PubMed Web of Science ®Google Scholar
• Fox C, Kramer RM, Barnes VL, Dowling QM, Vedvick TS. Working together: interactions between vaccine antigens and adjuvants. Ther Adv Vaccines. 2013;1(1):7–20.
   PubMedGoogle Scholar
• Arepanris™ (H1N1 AS03-adjuvanted H1N1 pandemic influenza vaccine) [package insert]. GlaxoSmithKline; 2010.
   Google Scholar
• Hugues S, Boissonnas A, Amigorena S, Fetler L. The dynamics of dendritic cell-T cell interactions in priming and tolerance. Curr Opin Immunol. 2006;18:491–495.
   PubMed Web of Science ®Google Scholar
• Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol. 2003;3:984–993.
   PubMed Web of Science ®Google Scholar
• Siegrist CA.. Vaccine immunology. In: Plotkin SA, Orenstein WA, and Offit PA, editors. Vaccines. 5th ed. Amsterdam: Elsevier Press; 2008:17–36.
   Google Scholar
• Weintraub A. Immunology of bacterial polysaccharide antigens. Carbohydr Res. 2003;338:2539–2547.
   PubMed Web of Science ®Google Scholar
• Zhou J, Lottenbach KR, Barenkamp SJ, Reason DC. Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun. 2005;72:3505–3514.
   Web of Science ®Google Scholar
• Shapiro-Shelef M, Calame K. Regulation of plasma-cell development. Nat Rev Immunol. 2005;5(3):230–242.
   Web of Science ®Google Scholar
• Huehn J, Siegmund K, Hamann A. Migration rules: functional properties of I and effector/memory-like regulatory T cell subsets. Curr Top Microbiol Immunol. 2005;293:89–114.
   PubMed Web of Science ®Google Scholar
• Chua JV, Chen WH. Herpes zoster vaccine for the elderly: boosting immunity. Aging Health. 2010;6:169–176.
   Google Scholar
• Levin MJ, Oxman MN, Zhang JH, et al; Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197:825–835.
   PubMed Web of Science ®Google Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521–5526.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 2003:529–588.
   Google Scholar
• Grewe M. Chronological ageing and photoageing of dendritic cells. Clin Exp Dermatol. 2001;26:608–612.
   PubMed Web of Science ®Google Scholar
• van Duin D, Shaw AC. Toll-like receptors in older adults. J Am Geriatr Soc. 2007;55:1438–1444.
   PubMed Web of Science ®Google Scholar
• Davila DR, Edwards CK 3rd, Arkins S, Simon J, Kelley KW. Interferon-gamma-induced priming for secretion of superoxide anion and tumor necrosis factor-alpha declines in macrophages from aged rats. FASEB J. 1990;4(11):2906–2911.
   Web of Science ®Google Scholar
• Tasat DR, Mancuso R, O’Connor S, Molinari B. Age-dependent changes in reactive oxygen species and nitric oxide generation by rat alveolar macrophages. Aging Cell. 2003;2:159–164.
   PubMed Web of Science ®Google Scholar
• Kissin E, Tomasi M, McCartney-Francis N, Gibbs CL, Smith PD. Age-related decline in murine macrophage production of nitric oxide. J Infect Dis. 1997;175:1004–1007.
   PubMed Web of Science ®Google Scholar
• Agrawal A, Agrawal S, Gupta S. Dendritic cells in human aging. Exp Gerontol. 2007;42(5):421–426.
   Web of Science ®Google Scholar
• Renshaw M, Rockwell J, Engleman C, Gewirtz A, Katz J, Sambhara S. Cutting edge: impaired Toll-like receptor expression and function in aging. J Immunol. 2002;169(9):4697–4701.
   PubMed Web of Science ®Google Scholar
• Panda A, Qian F, Mohanty S, et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol. 2010;184(5):2518–2527.
   PubMed Web of Science ®Google Scholar
• Cao W, Kim JH, Chirkova T, et al. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev Vaccines. 2011;10(11):1529–1537.
   PubMed Web of Science ®Google Scholar
• Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5:133–139.
   PubMed Web of Science ®Google Scholar
• Cambier J. Immunosenescence: a problem of lymphopoiesis, homeostasis, microenvironment and signaling. Immunol Rev. 2005;205:5–6.
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46(7):1078–1084.
   PubMed Web of Science ®Google Scholar
• Lelic A, Verschoor CP, Ventresca M, et al. The polyfunctionality of human memory CD8+ T cells elicited by acute and chronic virus infections is not influenced by age. PloS Pathog. 2012;8(12):e1003076.
   PubMed Web of Science ®Google Scholar
• Han S, Yang K, Ozen Z, et al. Enhanced differentiation of splenic plasma cells but diminished long-lived high-affinity bone marrow plasma cells in aged mice. J Immunol. 2003;170:1267–1273.
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM. The effect of age on the cognate function of CD4+ T cells. Immunol Rev. 2005;205:220–228.
   PubMed Web of Science ®Google Scholar
• Frasca D, Riley RL, Blomberg BB. Humoral immune response and B- cell functions including immunoglobulin class switch are downregulated in aged mice and humans. Semin Immunol. 2005;17:378–384.
   PubMed Web of Science ®Google Scholar
• Labrie JE 3rd, Sah AP, Allman DM, Cancro MP, Gerstein RM. Bone marrow microenvironmental changes underlie reduced RAG-mediated recombination and B cell generation in aged mice. J Exp Med. 2004;200:411–423.
   PubMed Web of Science ®Google Scholar
• Steinmann GG, Klaus B, Müller-Hermelink HK. The involution of the ageing human thymic epithelium is independent of puberty: a morphometric study. Scand J Immunol. 1985;22:563–575. ?
   PubMed Web of Science ®Google Scholar
• Lazuardi L, Jenewein B, Wolf AM, Pfister G, Tzankov A, Grubeck- Loebenstein B. Age-related loss of naïve T cells and dysregulation of T-cell/B-cell interactions in human lymph nodes. Immunology. 2005;114:37–43.
   PubMed Web of Science ®Google Scholar
• Haynes L, Linton, PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from I T cells of aged mice. J Exp Med. 1999;190:1013–1024.
   PubMed Web of Science ®Google Scholar
• Eaton SM, Burns EM, Kusser K, Randall TD, Haynes L. Age-related defects in CD4 T cell cognate helper function lead to reductions in humoral responses. J Exp Med. 2004;200:1613–1622.
   PubMed Web of Science ®Google Scholar
• Haynes L, Eaton SM, Burns EM, Randall TD, Swain SL. CD4 T cell memory derived from young I cells functions well into old age, but memory generated from aged I cells functions poorly. Proc Natl Acad Sci U S A. 2003;100(25):15053–15058.
   PubMed Web of Science ®Google Scholar
• Decman V, Laidlaw BJ, Doering TA, et al. Defective CD8 T cell responses in aged mice are due to quantitative and qualitative changes in virus-specific precursors. J. Immunol. 2012;188:1933–1941.
   Web of Science ®Google Scholar
• Cicin-Sain L, Smyk-Pearson S, Currier N, et al. Loss of I T cells and repertoire constriction predict poor response to vaccination in old primates. J Immunol. 2010;184:6739–6745.
   Web of Science ®Google Scholar
• Khan N, Hislop A, Gudgeon N, et al. Herpesvirus-specific CD8 T cell immunity in old age: cytomegalovirus impairs the response to a co- resident EBV infection. J Immunol. 2004;173:7481–7489.
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O’Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75(24):12182–12187.
   PubMed Web of Science ®Google Scholar
• Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with (+)CD28(-) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J. Immunol. 2002;168:5893–5899.
   PubMed Web of Science ®Google Scholar
• Almanzar G, Schwaiger S, Jenewein B, et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol. 2005;79(6):3675–3683.
   Web of Science ®Google Scholar
• Trzonkowski P, Mysliwska J, Szmit E, et al. Association between cytomegalovirus infection, enhanced proinflammatory response and low level of anti-hemagglutinins during the anti-influenza vaccination – an impact of immunosenescence. Vaccine. 2003;21(25–26):3826–3836.
   PubMed Web of Science ®Google Scholar
• Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol. 2008;29(8):357–365.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32(9):2045–2051.
   PubMed Web of Science ®Google Scholar
• Yendes S, Tuomanen EI, Winderink R, et al. Preinfection systemic inflammatory markers and risk of hospitalization due to pneumonia. Am J Respir Crit Care Med. 2005;172(11):1440–1446.
   Web of Science ®Google Scholar
• Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13:875–887.
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel JP, Pawelec G, Solana R. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res. 2009;21(3):201–209.
   Web of Science ®Google Scholar
• Song X, Mitnitski A, Rockwood K. Prevalence and 10-year outcomes of frailty in older adults in relation to deficit accumulation. J Am Geriatr Soc. 2010;58(4):681–687.
   PubMed Web of Science ®Google Scholar
• Yao X, Hamilton RG, Weng N, et al. Frailty is associated with impairment of vaccine-induced antibody response and increase in post-vaccination influenza infection in community-dwelling older adults. Vaccine. 2011;29(31):5015–5021.
   Web of Science ®Google Scholar
• Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure of aging. ScientificWorldJournal. 2001;1:323–336.
   PubMedGoogle Scholar
• Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr. 2008;8:24.
   PubMedGoogle Scholar
• Li H, Manwani B, Leng SX. Frailty, inflammation, and immunity. Aging Dis. 2011;2(6):466–473.
   PubMed Web of Science ®Google Scholar
• Visser M, Pahor M, Taaffe DR, et al. Relationship of interleukin-6 and tumor necrosis factor-alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J Gerontol A Biol Sci Med Sci. 2002;57(5):M326–M332.
   PubMed Web of Science ®Google Scholar
• Harris TB, Ferrucci L, Tracy RP, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106(5):506–512.
   PubMed Web of Science ®Google Scholar
• Ligthart GJ, Corberand JX, Geertzen HG, Meinders AE, Knook DL, Hijmans W. Necessity of the assessment of health status in human immunogerontological studies: evaluation of the SENIEUR protocol. Mech Ageing Dev. 1990;55(1):89–105.
   Web of Science ®Google Scholar
• Keitel W, Atmar R, Cate T, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006;166(10):1121–1127.
   PubMedGoogle Scholar
• Falsey A, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200(2):172–180.
   PubMed Web of Science ®Google Scholar
• Roos-Van Eijndhoven DG, Cools HJ, Westendorp RG, Ten Cate-Hoek AJ, Knook DL, Remarque EJ. Randomized controlled trial of seroresponses to double dose and booster influenza vaccination in frail elderly subjects. J Med Virol. 2001;63:293–298.
   Web of Science ®Google Scholar
• Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H. Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial. Vaccine. 2000;18:1700–1706.
   PubMed Web of Science ®Google Scholar
• Bergen RE, Diaz PS, Arvin AM. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis. 1990;162:1049–1054.
   Web of Science ®Google Scholar
• Kang I, Hong MS, Nolasco H, et al. Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine. J Immunol. 2004;173:673–681. ?
   PubMed Web of Science ®Google Scholar
• Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine. 2008;26(43):5521–5526.
   PubMed Web of Science ®Google Scholar
• Fedson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines. Philadelphia: Saunders; 2003:529–588.
   Google Scholar
• Ikonen N, Strengell M, Kinnunen L, et al. High frequency of cross-reacting antibodies against 2009 pandemic influenza A(H1N1) virus among the elderly in Finland. Euro Surveill. 2010;15(5):19478.
   Google Scholar
• Kaml M, Weiskirchner I, Keller M, et al. Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006;24:6808–6811.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Brokstad KA, Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol. 2004;59:1–15.
   PubMed Web of Science ®Google Scholar
• Bellanti JA, Zeligs BJ, Mendez de Inocencio J, Omidvar BM, Omidvar J, Awasum M. Alternative routes of immunization for prevention of infectious diseases: a new paradigm for the 21st century. Allergy Asthma Proc. 2011;22(3):173–176.
   Google Scholar
• Holland D, Booy R, De Looze F, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis. 2008;198(5):650–658.
   PubMed Web of Science ®Google Scholar
• Belshe RB, Newman FK, Cannon J, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med. 2004;351:2286–2294.
   PubMed Web of Science ®Google Scholar
• Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004;351:2295–2301.
   PubMed Web of Science ®Google Scholar
• Panda A, Arjona A, Sapey E, et al. Human innate immunosenescence: causes and consequences for immunity in old age. Trends Immunol. 2009;30:325–333.
   PubMed Web of Science ®Google Scholar
• Corrigan EM, Clancy RL. Is there a role for a mucosal influenza vaccine in the elderly? Drugs Aging. 1999;15(3):169–181.
   Web of Science ®Google Scholar
• Behzad H, Huckriede AL, Haynes L, et al. GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis. 2012;205(3):466–473.
   PubMed Web of Science ®Google Scholar
• Kuper CF, Koornstra PJ, Hameleers DM, et al. The role of nasopharyngeal lymphoid tissues. Immunol Today. 1992;13:219–224.
   PubMedGoogle Scholar
• Brandtzaeg P. Basic mechanisms of mucosal immunity – a major adaptive defense system. Immunologist. 1995;3:89–96.
   Google Scholar
• McGhee JR, Kiyono H. Mucosal Immunology. Fundamental Immunology. Waltham, MA: Academic Press; 1998.
   Google Scholar
• McGhee JR, Kiyono H. New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis. 1993;2:55–73.
   PubMedGoogle Scholar
• Kunkel EJ, Butcher EC. Plasma-cell homing. Nat Rev Immunol. 2003;3:822−829.
   Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med. 2005;11:S45–S53.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist®; Fluenz™): a review of its use in the prevention of seasonal influenza in children and adults. Drugs. 2011;71(12):1591–1622.
   PubMed Web of Science ®Google Scholar
• Higgins DA, Carlson JR, van Nest G. MF59 enhances the immunogenicity of influenza vaccine in both young and old mice. Vaccine. 1996;14:478–484.
   PubMed Web of Science ®Google Scholar
• Cataldo DM, Van Nest G. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. Vaccine, 1997;15:1710–1715.
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines. 2003;2(2):197–203.
   PubMedGoogle Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol. 2004;82:488–496.
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G, O’Hagan DT. MF59: a safe and potent adjuvant for human use. In: Schijns V, O’Hagan DT, editors. Immunopotentiators in Modern Medicines. Amsterdam: Elsevier Press; 2005.
   Google Scholar
• Dupuis M, Denis-Mize K, LaBarbara A, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol. 2001;31:2910–2918.
   PubMed Web of Science ®Google Scholar
• Seubert A, Monaci E, Pizza M, O’Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol. 2008;180:5402–5412.
   PubMed Web of Science ®Google Scholar
• Mosca F, Tritto E, Muzzi A, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A. 2008;105:10501–10506.
   PubMed Web of Science ®Google Scholar
• Kovaiou RD, Herndler-Brandstetter D, Grubeck-Loebenstein B. Age-related changes in immunity: implications for vaccination in the elderly. Expert Rev Mol Med. 2007;9(3):1–17.
   Google Scholar
• Schreibelt G, Benitez-Ribas D, Schuurhuis D, et al. Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood. 2010;116:564–574.
   PubMed Web of Science ®Google Scholar
• Herndler-Brandsetter D, Cioca DP, Grubeck-Loebenstein B. Immunizations in the elderly: do they live up to their promise? Wien Med Wochenschr. 2006;156:130–141.
   Google Scholar
• Taylor DN, Treanor JJ, Sheldon EA, et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine. 2012;30:5761–5769.
   PubMed Web of Science ®Google Scholar
• Aspinall R, Pido-Lopez J, Imami N, et al. Old rhesus macaques treated with interleukin-7 show increased TREC levels and respond well to influenza vaccination. Rejuvenation Res. 2007;10:5–17.
   PubMed Web of Science ®Google Scholar
• Ben-Yehuda A, Joseph A, Zeira E, et al. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults. J Med Virol. 2003;69:560–567.
   PubMed Web of Science ®Google Scholar
• Levine MM, Sztein MB. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol. 2004;5(5):460–464.
   PubMed Web of Science ®Google Scholar
• Albers R, van der Wielen RP, Brink EJ, Hendriks HF, Dorovska-Taran VN, Mohede IC. Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid (CLA) isomers on immune function in healthy men. Eur J Clin Nutr. 2003;57:595–603.
   PubMed Web of Science ®Google Scholar
• Marko MG, Ahmed T, Bunnell SC, et al. Age-associated decline in effective immune synapse formation of CD4(+) T cells is reversed by vitamin E supplementation. J Immunol. 2007;178:1443–1449.
   PubMed Web of Science ®Google Scholar
• Messaoudi I, Warner J, Fischer M, et al. Delay of T cell senescence by caloric restriction in aged long-lived nonhuman primates. Proc Natl Acad Sci U S A. 2006;103:19448–19453.
   Web of Science ®Google Scholar
• Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179.
   PubMed Web of Science ®Google Scholar
• Andrew D, Aspinall R. IL-7 and not stem cell factor reverses both the increase in apoptosis and the decline in thymopoiesis seen in aged mice. J Immunol. 2001;166:1524–1530.
   PubMed Web of Science ®Google Scholar
• Ongrádi J, Stercz B, Kövesdi V, Vértes L. Immunosenescence and vaccination of the elderly II. New strategies to restore age-related immune impairment. Acta Microbiol Immunol Hung. 2009;56(4):301–312.
   Web of Science ®Google Scholar
• Foy TM, Aruffo A, Bajorath J, Buhlmann JE, Noelle RJ. Immune regulation by CD40 and its ligand GP39. Annu Rev Immunol. 1996;14:591–617.
   PubMed Web of Science ®Google Scholar
• Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303(10):943–950.
   PubMed Web of Science ®Google Scholar
• Carman WF, Elder AG, Wallace LA, et al. Effects of influenza vaccination of health-care workers on mortality of elderly people in long-term care: a andomized controlled trial. Lancet. 2000;355(9198):93–97.
   PubMed Web of Science ®Google Scholar
• Burls A, Jordan R, Barton P, et al. Vaccinating healthcare workers against influenza to protect the vulnerable – is it a good use of healthcare resources? A systematic review of the evidence and an economic evaluation. Vaccine. 2006;24(19):4212–4221.
   Web of Science ®Google Scholar
• Walter ND, Taylor TH Jr, Dowel SF, Mathis S, Moore MR; Active Bacterial Core Surveillance System Team. Holiday spikes in pneumococcal disease among older adults. N Engl J Med. 2009;361:2584–2585.
   Google Scholar
• Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol. 1982;115(5):736–751.
   PubMed Web of Science ®Google Scholar
• Ghendon YZ, Kaira AN, Elshina GA. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect. 2006;134(1):71–78.
   Web of Science ®Google Scholar
• Lang PO, Aspinall R. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules? Expert Rev Vaccines. 2012;11(2):167–176.
   PubMed Web of Science ®Google Scholar
• Mouton CP, Bazaldua OV, Pierce B, Espino DV. Common infections in older adults. Health Care Food Nutr Focus. 2001;8(3):1, 3–7.
   Google Scholar